📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
Kaken Pharmaceutical Co Ltd
Kaken Pharmaceutical's GHG Emissions Data Preview
In 2023, Kaken Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Kaken Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind Kaken Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Kaken Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Insights into Kaken Pharmaceutical's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions ofKaken Pharmaceutical amounted to21,408metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Kaken Pharmaceuticaldecreased by 1.2%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
Kaken Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Kaken Pharmaceutical's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Kaken Pharmaceutical were 11,069 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Has Kaken Pharmaceutical reduced its Scope 1 emissions over time?
Since 2019, Kaken Pharmaceutical's Scope 1 emissions have decreased by 14.33%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year(2022), Kaken Pharmaceutical's Scope 1 emissions decreased by 7.51%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
What are Kaken Pharmaceutical's Scope 2 emissions?
In 2023, Kaken Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 10,339 tCOâ‚‚e without specifying the calculation method.a
Has Kaken Pharmaceutical reduced its Scope 2 emissions over time?
Since 2019, Kaken Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method)have remained relatively stable, indicating that Kaken Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year(2022), Kaken Pharmaceutical's Scope 2 emissions(Unspecified Calculation Method) have remained relatively stable, indicating that Kaken Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a
What methodology does Kaken Pharmaceutical use for Scope 2 reporting?
In 2023, Kaken Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
Kaken Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Kaken Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers
In 2023, Kaken Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 11,069 tCOâ‚‚e and total revenues of USD 548 millions. This translates into an emissions intensity of 20.2 tCOâ‚‚e per millions USD.a
Kaken Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers
How does Kaken Pharmaceutical's GHG emissions intensity compare to its peers?
In 2023, Kaken Pharmaceutical reported a Scope 1 emissions intensity of 20.2 tCOâ‚‚e per millions USD. Compared to the peer group median of 4.84, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
Where does Kaken Pharmaceutical rank on GHG emissions intensity within its industry?
In 2023, Kaken Pharmaceutical ranked 23 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a
This places Kaken Pharmaceutical among the least efficient performers, with one of the highest emissions intensities in its sector.a